Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.99 is in line with its 5-year average of -0.93, around the middle of its 5-year range (-1.66–-0.01).
28.52% above its 12-month average of -1.39.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.38.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 16 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.99
EARNINGS PER SHARE (EPS) AVG TTM
-1.39
EARNINGS PER SHARE (EPS) AVG 3Y
-1.39
EARNINGS PER SHARE (EPS) AVG 5Y
-0.93
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+28.52%
CURRENT VS 3Y AVG
+28.90%
CURRENT VS 5Y AVG
-6.13%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Orchestra BioMed Holdings, Inc.
Market Cap
$348.81M
Earnings Per Share (EPS)
-0.99
TTM Avg
-1.39
3Y Avg
-1.39
5Y Avg
-0.93
Market Cap
$350.03M
Earnings Per Share (EPS)
1.48
TTM Avg
1.49
3Y Avg
2.03
5Y Avg
3.82
Market Cap
$346.88M
Earnings Per Share (EPS)
-0.29
TTM Avg
-0.18
3Y Avg
-0.18
5Y Avg
-0.18
Market Cap
$344.82M
Earnings Per Share (EPS)
-0.92
TTM Avg
-2.05
3Y Avg
-3.17
5Y Avg
-3.94
Market Cap
$353.49M
Earnings Per Share (EPS)
-0.25
TTM Avg
-0.22
3Y Avg
-0.27
5Y Avg
-0.28
Market Cap
$354.03M
Earnings Per Share (EPS)
-2.41
TTM Avg
-4.66
3Y Avg
-5.40
5Y Avg
-4.56
Market Cap
$354.03M
Earnings Per Share (EPS)
0.36
TTM Avg
0.33
3Y Avg
0.27
5Y Avg
0.36
Market Cap
$359.07M
Earnings Per Share (EPS)
-0.14
TTM Avg
-0.19
3Y Avg
-0.48
5Y Avg
-0.56
Market Cap
$359.28M
Earnings Per Share (EPS)
-3.31
TTM Avg
-3.43
3Y Avg
-2.65
5Y Avg
-2.61
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Orchestra BioMed Holdings, Inc. (OBIO) | $348.81M | -0.99 | -1.39 | -1.39 | -0.93 |
| Embecta Corp. (EMBC)vs › | $350.03M | 1.48 | 1.49 | 2.03 | 3.82 |
| Turn Therapeutics Inc. (TTRX)vs › | $346.88M | -0.29 | -0.18 | -0.18 | -0.18 |
| Relmada Therapeutics, Inc. (RLMD)vs › | $344.82M | -0.92 | -2.05 | -3.17 | -3.94 |
| Ocugen, Inc. (OCGN)vs › | $353.49M | -0.25 | -0.22 | -0.27 | -0.28 |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $354.03M | -2.41 | -4.66 | -5.40 | -4.56 |
| Viemed Healthcare, Inc. (VMD)vs › | $354.03M | 0.36 | 0.33 | 0.27 | 0.36 |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $359.07M | -0.14 | -0.19 | -0.48 | -0.56 |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $359.28M | -3.31 | -3.43 | -2.65 | -2.61 |
| Opus Genetics, Inc. (IRD)vs › | $361.26M | N/A | -1.30 | -1.38 | -1.95 |
Trailing EPS (TTM)
$-0.99
Forward EPS (Est.)
$-1.52
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -1.11 |
| 2024-12-31 | -1.66 |
| 2023-12-31 | -1.48 |
| 2022-12-31 | -1.32 |
| 2021-12-31 | -0.02 |
| 2020-12-31 | -0.01 |
